NHNoreen J. Hickok

Noreen J. Hickok

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Noreen J. Hickok has a total of 242 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Top Cited Papers

    2025 International Consensus Meeting on Musculoskeletal Infection: Summary From Biofilm Workgroup on Treatment of Biofilm‐Related Infection and Preclinical Models

    by Jessica Amber Jennings, Hesham Abdelbary, Fatima S. Abdulla, Orfan Arafah, Tarek Benzouak, Hyonmin Choe, Tom Coenye, Débora C. Coraça‐Huber, Lorenzo Drago, R. Gustavo Garcia, et al.

    Despite advancements in surgical techniques, musculoskeletal infections (MSKI) remain severe complications following orthopedic surgery, imposing a substantial financial and personal burden on patients and healthcare systems globally. To establish the current state of knowledge in this field, International Consensus Meetings (ICM) were held in 2013, 2018, and 2025, including a Biofilm Section focused on establishing state‐of‐the‐art basic science and translational research. The latest ICM utilized a 2‐year‐long Delphi process that commenced on May 31, 2023, and culminated in an in‐person meeting involving voting on 30 questions by 47 delegates on May 8–10, 2025, in Istanbul, Turkey. Following the voting process, the Biofilm Section formed three workgroups (Biofilm Basic Science, Biofilm Treatment, and Research Priorities) to interpret the results and disseminate the findings in Consensus Articles that highlight priorities. The following is the summation of the Biofilm Treatment Workgroup, which aims to shape future pre‐clinical MSKI research directions and grant funding with respect to: (1) elevating scientific rigor to ensure reproducibility and high‐quality data in preclinical research; (2) transitioning mature therapeutic concepts into rigorous in vivo models to definitively prove their clinical feasibility; and (3) accelerating the development of novel molecular targets and advanced drug‐delivery systems. Finally, the workgroup acknowledged a critical shift in the funding landscape. As government support faces future challenges, there is an urgent need for increased investment from industry and philanthropic partners. Such support is essential to develop effective treatments for serious orthopedic infections and to improve outcomes for patients facing life‐altering illnesses.


  • Open Access

    Controlled Antibiotic Release From Emulsion‐Loaded Alginate and Fibrin Hydrogels Using Ultrasound

    by Ziba Ghareh Nazi Fam, Asia Winslow, Mario L. Fabiilli, Sam Varghese, Brian E. Oeffinger, Flemming Forsberg, Noreen J. Hickok, Lauren J. Delaney

    Postoperative infections remain a major complication after spinal fusion surgery, often caused by biofilm‐forming bacteria that resist short‐term antibiotic prophylaxis. Vancomycin (VAN) is sometimes delivered locally during surgery; however, levels diminish rapidly, leaving patients vulnerable to late‐onset infections. We developed a composite hydrogel integrating perfluorohexane‐based emulsions within alginate or fibrin matrices to enable both sustained and ultrasound‐triggered VAN release. Water‐in‐oil‐in‐water emulsions were prepared using fluorosurfactant‐stabilized perfluorohexane as the volatile oil phase, then embedded in hydrogels and exposed to ultrasound (2.5 MHz, 5.5 MPa peak negative pressure) to initiate acoustic droplet vaporization for triggered release. Drug release was quantified spectrophotometrically and with fluorescent‐labeled VAN, while antibacterial efficacy was tested against Staphylococcus aureus . Hydrogels directly loaded with free VAN exhibited burst release (~55%–67% within 24 h) followed by limited sustained release, which is suboptimal for prolonged coverage. In contrast, emulsion‐loaded hydrogels reduced premature leakage, retaining > 70% VAN on Day 1 and providing gradual baseline release. Ultrasound application enhanced VAN release up to 8.75‐fold in alginate and 27.5‐fold in fibrin hydrogels after 7 days ( p < 0.0001), supporting both continuous and on‐demand delivery. Only alginate‐emulsion hydrogels showed measurable antibacterial activity, as drug‐matrix interactions in fibrin prevented release; ultrasound‐treated samples displayed significantly greater efficacy over 7 days ( p < 0.05 vs. no ultrasound). This dual‐mode delivery platform enables spatial and temporal control of VAN release, combining early prophylaxis with ultrasound‐triggered reinforcement, and holds promise for improving infection prevention in orthopedic surgeries by aligning drug delivery with clinical timelines.


  • Top Cited Papers

    2025 International Consensus Meeting on Musculoskeletal Infection: Summary From the Biofilm Workgroup on Biofilm Formation, Persistence, and Host‐Environment Interactions

    by Gowrishankar Muthukrishnan, Débora C. Coraça‐Huber, Gerald J. Atkins, Ahmad Abbaszadeh, Armita A. Abedi, Ezzuddin Abuhussein, Joshua S. Bingham, Kyle H. Cichos, Tom Coenye, Lorenzo Drago, et al.

    Musculoskeletal infection (MSKI) remains a major problem after trauma and elective orthopedic surgery. Chronic MSKI is related to the formation of biofilm, which impairs diagnosis and effective treatments. Therefore, to understand and communicate global standards and best practices, the 2025 International Consensus Meeting (ICM) on MSKI created a Biofilm Section to address crucial aspects of biofilm biology pertaining to its mechanisms of drug resistance and immune evasion, and potential approaches to overcome them. This featured a 2‐year process, with final voting and discussion on May 8–10, 2025, in Istanbul, Turkey. This Consensus Article is the effort of the Biofilm Basic Mechanisms Workgroup, which interpreted the results on ICM questions related to (1) the infectious microenvironment; (2) appropriate inocula in preclinical research; (3) biofilm behavior in infected tissues; and (4) synergy within biofilms and with other comorbidities. Collectively, we find that this field has the necessary research tools to discover the pathophysiology of orthopedic implant‐associated biofilm development and maturation, perform clinically relevant studies in animal models, and elucidate mechanisms that allow opportunistic infections in compromised tissues and patients with other health issues.


  • Open Access

    Delayed delivery of antibiotics by ultrasound-mediated rupture of polylactic acid pockets: In vitro and in vivo studies

    by Selin Isguven Billmyer, Priscilla Machado, Ryan E. Tomlinson, Lauren J. Delaney, Ji-Bin Liu, Alexander H. Harris, Eric McLaughlin, Noreen J. Hickok, Flemming Forsberg

    Surgical site infections are a devastating complication of instrumented orthopaedic surgery, particularly in the spine. Bacterial biofilms, once formed on the implant surfaces, exhibit antibiotic tolerance and immune escape, which lead to treatment challenges. Up to 9% of instrumented spine surgeries result in infection, despite the use of systemic antibiotics and local, powdered antibiotics for prophylaxis. The bacteria that survive the initial prophylaxis may be susceptible to a second, high dose of antibiotic prophylaxis prior to establishing at the site. Hence, we designed a local drug delivery system consisting of polylactic acid (PLA) film pockets that can be noninvasively triggered ( i.e. , ruptured) by the external application of ultrasound (US) following a delay of up to 6 days. We found that thin PLA films (24 ± 4.5 µm) with embedded vancomycin (VAN) powder assembled in a conical pocket shape best allowed for stability and rupturability of this US-mediated delivery system in vitro (92% US-triggered rupture of PLA-VAN pockets vs 31% of neat PLA pockets, p < 0.0001). VAN-embedded PLA films exhibited decreased strength and toughness (3.47 J/mm 3 vs 0.68 J/mm 3 , p < 0.0001) and surface VAN was rapidly released upon submersion, adding an additional layer of protection against bacterial colonization of the device. Finally, a pilot in vivo study in five rabbits demonstrated the feasibility of the design, but the stability of neat PLA and PLA-VAN pockets were varied (9/15 of all pockets were intact by Day 3). All of the 5 intact pockets (3 neat PLA and 2 PLA-VAN) that were allocated for insonation ruptured following US (100%). Overall, this design has the potential for use in targeting orthopaedic infections as well as for US-triggered bolus drug release for prophylaxis in high risk cases.


  • In memoriam: Paul Stoodley—Tribute to a friend

    by Noreen J. Hickok, Antonia F. Chen, Kordo Saaed, Kenneth Urish, Thomas P. Schaer

  • Minocycline-rifampin–impregnated penile prosthesis surfaces retain antimicrobial activity following irrigation with 0.05% chlorhexidine gluconate and antibiotic solutions

    by Brian H Im, Analyse Giordano, Sohan Shah, Samone Guillaume, Rachel Evans, Noreen J Hickok, Paul H Chung

    0.05% Chlorhexidine gluconate (CHG; Irrisept [IrriMax]) is a commercial wound irrigation solution approved by the Food and Drug Administration that has seen recent adoption in the field of prosthetic urology; however, no study has evaluated whether 0.05% CHG is compatible with the minocycline-rifampin–impregnated surface (InhibiZone) of the AMS 700 penile prosthesis (Boston Scientific). To evaluate whether 0.05% CHG alters the antibiotic efficacy of the minocycline-rifampin–impregnated penile prosthesis surface. Discs (8 mm) were taken by a punch biopsy (Sklar) from sterile penile prosthesis reservoirs whose surfaces had been impregnated with rifampin and minocycline. Discs (n = 10) were suspended in 0.05% CHG, vancomycin and gentamicin, or normal saline for 2 minutes to simulate intraoperative irrigation. Discs were then rinsed in normal saline to remove any unbound solution and incubated with methicillin-sensitive Staphylococcus aureus for 48 hours. Adherent surface bacteria were suspended by shaking in a 0.3% Tween 20 solution, serially diluted, plated onto 3M PetriFilms, and counted. Kirby-Bauer disc diffusion assays were conducted to generalize findings across various organisms. Outcomes included (1) bacterial adherence to the implant surface measured as bacterial counts (in colony-forming units per milliliter) and (2) bacterial growth reduction measured as zones of inhibitions (in millimeters). Incubation of implant surfaces in 0.05% CHG did not alter recovered bacterial counts as compared with normal saline and vancomycin/gentamycin. Similarly, within a single bacterial species, 0.05% CHG and vancomycin/gentamycin did not alter zone-of-inhibition measurements in Kirby-Bauer disc diffusion studies. This study demonstrates in vitro that 0.05% CHG may be used directly on the minocycline-rifampin–impregnated surface without altering the antibiotic efficacy of the coating. Strengths include that this is the first study to evaluate if 0.05% CHG affected the minocycline-rifampin–impregnated surface. Limitations include the use of in vitro studies, which serve as a proxy for in vivo practices and may not be entirely accurate or translatable in a clinical setting. 0.05% CHG does not alter the antimicrobial activity of the minocycline-rifampin–impregnated surface as compared with vancomycin/gentamycin and normal saline in vitro; however, its efficacy in clinical practice remains to be evaluated.


  • Antibiotic dip and irrigation solutions confer increased antimicrobial efficacy of inflatable penile prosthesis hydrophilic surfaces compared with 0.05% chlorhexidine gluconate

    by Rishabh Simhal, Brian H Im, Sohan Shah, Samone Guillaume, Carlos Perez Kerkvliet, Rachel Evans, Noreen J Hickok, Paul H Chung

    Chlorhexidine gluconate (CHG) (0.05%) has recently been suggested as both a dip for the hydrophilic surface and an irrigation solution in the setting of penile prosthesis (PP) surgery. The study sought to compare the antimicrobial efficacy of 0.05% CHG with vancomycin and gentamicin (VG) antibiotics as dip and/or irrigation solutions in the setting of a hydrophilic PP surface in vitro. Sterile PPs with a hydrophilic coating were obtained. A series of experiments were performed to evaluate the efficacy of normal saline (NS), 0.05% CHG, or VG as dip and/or irrigation solutions to reduce methicillin-sensitive Staphylococcus aureus adhesion to PP surfaces. The 8-mm discs from PPs were incubated in 105 colony-forming units/mL of methicillin-sensitive S aureus for 48 hours, plated, and counted. Disc-diffusion tests were conducted by suspending 6-mm discs for 2 minutes in NS, 0.05% CHG, or VG, then placing them coated side down onto plates streaked with the following organisms: methicillin-sensitive S aureus, S epidermidis, Enterococcus, and Escherichia coli. After 24 hours of growth, zones of inhibition were measured. We found average bacterial counts (colony-forming units/mL) and zones of inhibition (mm) following a series of treatment protocols of PP discs. PP discs dipped in VG reduced bacterial adhesion to the implant surface >0.05% CHG (~5.5 log vs ~1.5 log; P < .01). Discs irrigated with either 0.05% CHG or NS removed all dip solution adsorbed to the hydrophilic surface, allowing bacterial growth. VG irrigation adsorbed to the hydrophilic surface even after 0.05% CHG or NS dips, reducing bacterial adherence (~3 log). Dipping and irrigating discs with VG was most effective in reducing adherent bacteria (~5.5 log) and was the only irrigation that showed antimicrobial activity. VG, when used both as a prophylactic dip and as an intraoperative irrigation solution for hydrophilic penile implant surfaces, has improved efficacy to 0.05% CHG and NS. This is the first study to compare the use of VG, 0.05% CHG, and NS as prophylactic dips and intraoperative irrigations for hydrophilic penile implant surfaces. Limitations include the use of in vitro studies, which serve as a proxy for in vivo practices and may not be entirely accurate nor translatable clinically. We demonstrated the superior efficacy of VG as a combined dip and irrigation solution for hydrophilic penile implant surfaces compared with 0.05% CHG.


  • Open Access

    Exploring the mechanical strength, antimicrobial performance, and bioactivity of 3D-printed silicon nitride-PEEK composites in cervical spinal cages

    by Cemile Basgul, Paul DeSantis, Tabitha Derr, Noreen J. Hickok, Ryan M. Bock, Steven M. Kurtz

    In this study, our goal was to assess the suitability of a polyether-ether-ketone (PEEK) and silicon nitride (Si3N4) polymer composite for antimicrobial three-dimensional (3D)-printed cervical cages. Generic cage designs (PEEK and 15 vol.% Si3N4-PEEK) were 3D-printed, including solid and porous cage designs. Cages were tested in static compression, compression shear, and torsion per ASTM F2077. For antibacterial testing, virgin and composite filament samples were inoculated with Staphylococcus epidermidis and Escherichia coli. In vitro cell testing was conducted using MC3T3-E1 mouse preosteoblasts, where cell proliferation, cumulative mineralization, and osteogenic activity were measured. The 3D-printed PEEK and Si3N4-PEEK cages exhibited adequate mechanical strength for all designs, exceeding 14.7 kN in compression and 6.9 kN in compression shear. Si3N4-PEEK exhibited significantly lower bacterial adhesion levels, with a 93.9% reduction (1.21 log), and enhanced cell proliferation when compared to PEEK. Si3N4-PEEK would allow for custom fabrication of 3D-printed spinal implants that reduce the risk of infection compared to unfilled PEEK or metallic alloys.


  • Open Access

    The 2023 Orthopedic Research Society's international consensus meeting on musculoskeletal infection: Summary from the in vitro section

    by Noreen J. Hickok, Bingyun Li, Ebru Oral, Sebastian A. J. Zaat, David A. Armbruster, Gerald J. Atkins, Antonia F. Chen, Débora C. Coraça‐Huber, Tianhong Dai, Edward M. Greenfield, et al.

    Antimicrobial strategies for musculoskeletal infections are typically first developed with in vitro models. The In Vitro Section of the 2023 Orthopedic Research Society Musculoskeletal Infection international consensus meeting (ICM) probed our state of knowledge of in vitro systems with respect to bacteria and biofilm phenotype, standards, in vitro activity, and the ability to predict in vivo efficacy. A subset of ICM delegates performed systematic reviews on 15 questions and made recommendations and assessment of the level of evidence that were then voted on by 72 ICM delegates. Here, we report recommendations and rationale from the reviews and the results of the internet vote. Only two questions received a ≥90% consensus vote, emphasizing the disparate approaches and lack of established consensus for in vitro modeling and interpretation of results. Comments on knowledge gaps and the need for further research on these critical MSKI questions are included.


  • 2023 International Consensus Meeting on musculoskeletal infection: Summary from the treatment workgroup and consensus on treatment in preclinical models

    by Jessica Amber Jennings, Jacobus J. Arts, Ezzuddin Abuhussein, Volker Alt, Nicholas Ashton, Susanne Baertl, Sanjib Bhattacharyya, Jarrett D. Cain, Yogita Dintakurthi, Paul Ducheyne, et al.

    In vitro and in vivo studies are critical for the preclinical efficacy assessment of novel therapies targeting musculoskeletal infections (MSKI). Many preclinical models have been developed and applied as a prelude to evaluating safety and efficacy in human clinical trials. In performing these studies, there is both a requirement for a robust assessment of efficacy, as well as a parallel responsibility to consider the burden on experimental animals used in such studies. Since MSKI is a broad term encompassing infections varying in pathogen, anatomical location, and implants used, there are also a wide range of animal models described modeling these disparate infections. Although some of these variations are required to adequately evaluate specific interventions, there would be enormous value in creating a unified and standardized criteria to animal testing in the treatment of MSKI. The Treatment Workgroup of the 2023 International Consensus Meeting on Musculoskeletal Infection was responsible for questions related to preclinical models for treatment of MSKI. The main objective was to review the literature related to priority questions and estimate consensus opinion after voting. This document presents that process and results for preclinical models related to (1) animal model considerations, (2) outcome measurements, and (3) imaging.